New Potential of Chronic Cough Therapy in Postnasal Drip

Abstract

Respiratory tract diseases are often accompanied by cough. Cough may vary in duration and aetiology. The underlying causes of cough may be associated with upper and lower respiratory tract conditions. Besides, some types of coughs are not related to any respiratory disorder. Cough can be an underlying disease or only a symptom of a medical problem. It is no wonder why the antitussive drugs market is so huge. The main antitussive medications include antitussives themselves (centrally acting and peripherally acting drugs), drugs with an indirect cough suppressing action (bronchodilators, anti-inflammatory drugs, antiallergic agents, decongestants, etc.) and combination products. However, only few of them produce combined effects. This article presents a clinical study of the efficacy and safety of Rengalin, the released-activity combination drug having antitussive, anti-inflammatory and bronchodilator actions. The study enrolled patients with chronic cough arising from a postnasal drip syndrome. The study treatment was compared to the standard therapeutic strategy. The following parameters were assessed to determine statistical difference: daytime and night-time cough severity, a patient's general condition measured by the visual analog scale (VAS), and the number of patients with fully resolved cough by the end of the study treatment. Rengalin was found to increase the efficacy of treatment for chronic cough and improve quality of life in patients.